Sars-cov-2 disease adjuvant therapies and supplements breakthrough for the infection prevention

63Citations
Citations of this article
129Readers
Mendeley users who have this article in their library.

Abstract

The SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is a high-risk viral agent involved in the recent pandemic stated worldwide by the World Health Organization. The infection is correlated to a severe systemic and respiratory disease in many cases, which is clinically treated with a multi-drug pharmacological approach. The purpose of this investigation was to evaluate through a literature overview the effect of adjuvant therapies and supplements for the SARS-CoV-2 infection. The research has analyzed the advantage of the EK1C4, by also assessing the studies on the resveratrol, vitamin D, and melatonin as adjuvant supplements for long hauler patients’ prognosis. The evaluated substances reported important benefits for the improvement of the immune system and as a potential inhibitor molecules against SARS-CoV-2, highlighting the use of sartans as therapy. The adjuvant supplements seem to create an advantage for the healing of the long hauler patients affected by chronic symptoms of constant chest and heart pain, intestinal disorders, headache, difficulty concentrating, memory loss, and tachycardia.

Cite

CITATION STYLE

APA

Inchingolo, A. D., Inchingolo, A. M., Bordea, I. R., Malcangi, G., Xhajanka, E., Scarano, A., … Dipalma, G. (2021, March 1). Sars-cov-2 disease adjuvant therapies and supplements breakthrough for the infection prevention. Microorganisms. MDPI AG. https://doi.org/10.3390/microorganisms9030525

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free